Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 52793 (Primary) ; Itacitinib (Primary) ; Parsaclisib (Primary) ; Azacitidine; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone; Gemcitabine; Lenalidomide; Paclitaxel; Pomalidomide
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Pancreatic cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation

Most Recent Events

  • 01 Jul 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
  • 06 Apr 2020 Status changed from completed to discontinued.
  • 04 Sep 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top